Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 3/20 | 0.33 |
| ▸ | HRH1 | P35367 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10244310 | 0.86 | MTNR1A (0.33) | MTNR1AMTNR1BCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL10244695 | 0.81 | SMN1; SMN2 (0.41) | CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL10243404 | 0.78 | KDM4E (0.34) | MTNR1AMTNR1B | |
| SCHEMBL335843 | 0.78 | CYP2D6 (0.36) | CYP2D6HRH1KCNH2CHRM1HRH2 | |
| SCHEMBL10244037 | 0.76 | CYP1A2 (0.46) | MTNR1AMTNR1BCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL10243497 | 0.76 | SLC22A1 (0.43) | MTNR1AMTNR1BCYP2D6CYP1A2CYP3A4 | |
| SCHEMBL10243156 | 0.75 | ALDH1A1 (0.46) | CYP3A4 | |
| SCHEMBL10243510 | 0.74 | ALOX5 (0.40) | EPHX1 | |
| SCHEMBL10243580 | 0.74 | ACACB (0.49) | CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL10243433 | 0.73 | MAPT (0.43) | MTNR1AMTNR1BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | MTNR1A 2892/4885MTNR1B 2314/4885CYP2D6 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.